METAGLIP
LOE ApproachingNDAORALTABLET
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METAGLIP is an oral tablet approved in 2002 as a small-molecule NDA by Bristol Myers Squibb. The specific mechanism of action and indications are not documented in available data, limiting clinical characterization. This product represents a mature oral therapeutic from the early 2000s era.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a mature brand team likely focused on lifecycle extension or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
Started Jun 2005
36 enrolled
Healthy
Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
Started Jun 2005
36 enrolled
Healthy
Career Relevance
METAGLIP currently shows zero linked job openings, reflecting its mature lifecycle status and approaching LOE. Career opportunities on this product are limited to defensive sales and brand management roles as the franchise prepares for generic competition.
Brand Manager
Worked on METAGLIP at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.